NT5E and melanoma: Importantly, the substances we used to specifically block CD39 and CD73 activity are already being tested in vivo for other diseases: APCP was found to be highly beneficial in a mouse melanoma model [72] whereas the CD39-inhibitor ARL67156 has shown promise for the treatment of hepatic insulin resistance [73].